Clinical Trials

90 enrolled 15 charts

Sarcoma

Sarcoma, Ewing, Osteosarcoma

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04079712 2026-03-18

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03945773 2026-03-13

CaboPoint

127 enrolled 17 charts

Carcinoma, Renal Cell

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Dermatologic

Melanoma

NCT01068782 2026-02-25

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Phase 2 Terminated

19 enrolled 10 charts

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

36 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT04022343 2026-01-05

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

22 enrolled 16 charts

657 enrolled 57 charts 3 FDA

Carcinoma, Renal Cell

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

Carcinoma, Hepatocellular

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT03755791 2025-12-11

COSMIC-312

837 enrolled 14 charts

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05052723 2025-11-19

Cabozantinib and Pembrolizumab in Metastatic Pancreas

21 enrolled 12 charts

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT01935934 2025-10-01

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

102 enrolled 14 charts

Carcinoma, Endometrioid

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

187 enrolled 13 charts 1 FDA

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Phase 4 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT01896479 2025-09-02

EXAMINER

247 enrolled 14 charts

Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

NCT04164979 2025-08-11

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

34 enrolled 11 charts

Gastric Adenocarcinoma

NCT04400474 2025-06-19

CABATEN

CNSEndocrineHead & NeckNET

93 enrolled 17 charts

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT03141177 2025-06-06

CheckMate 9ER

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01441947 2025-05-25

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

68 enrolled 11 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04211337 2025-04-20

LIBRETTO-531

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT04804813 2025-04-11

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Completed

388 enrolled 20 charts

Carcinoma, Renal Cell

NCT04316182 2025-03-30

ACTION

24 enrolled 23 charts